Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O’Neal Comprehensive Cancer Center, shared an article by S. Lu on LinkedIn:
“Exciting developments in the management of unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC)!
The Phase III LAURA study, previously revealed that osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, significantly improves progression-free survival (PFS) and reduces the risk of central nervous system (CNS) progression when administered after definitive chemoradiotherapy (CRT). Updated analysis for CNS and distant metastases, now published in Annals of Oncology Annals of Oncology ESMO – European Society for Medical Oncology.
Key Findings:
- CNS Progression-Free Survival: Median CNS PFS was not reached with osimertinib, compared to 14.9 months with placebo. The hazard ratio (HR) for CNS PFS was 0.17, indicating an 83% reduction in the risk of CNS progression.
- Time to Death or Distant Metastases (TTDM): Osimertinib showed a clinically meaningful improvement in TTDM, with an HR of 0.21, suggesting a 79% reduction in the risk of distant metastases.
These results underscore osimertinib’s potential as a standard-of-care treatment following CRT in patients with unresectable stage III EGFR-mutated NSCLC, offering hope for improved outcomes and quality of life.”
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Authors: S. Lu, et al.
More posts featuring Aakash Desai.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023